Regeneron’s $8B Sanofi Deal & 73% Ovarian‑Cancer Success Spark Investor Momentum
Regeneron boosts growth with an $8bn Sanofi tie‑up and breakthrough ovarian‑cancer and obesity trials, sparking fresh investor interest.
3 minutes to read
REGENERON PHARMACEUTICALS